医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Irritable Bowel Syndrome (Event Driven)

2012年09月26日 AM02:01
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/6tdpwp/irritable_bowel) has announced the addition of Decision Resources, Inc’s new report “Irritable Bowel Syndrome (Event Driven)” to their offering.

Although a highly prevalent condition, irritable bowel syndrome (IBS) is marked by low diagnosis and treatment rates in the major pharmaceutical markets under study. Many patients self-medicate with OTC products, and many of the prescription drugs available to treat diagnosed patients offer suboptimal efficacy and side-effect profiles. Considerable commercial potential is available to companies that can develop and promote safe, effective therapies for this underserved and highly genericized market. Because of their premium prices, the launch of a few novel therapies will more than triple major-market IBS sales during our ten-year forecast period.

Key Topics Covered:

– Executive Summary

– 1 Etiology and Pathophysiology

– 2 Epidemiology and Patient Populations

– 3 Current Therapies and Medical Practice

– 4 Unmet Needs

– 5 Emerging Therapies

– 6 Market Outlook

– Appendix A Bibliography-Irritable Bowel Syndrome

– Appendix B Market Forecast Methodology

– Appendix C Experts InterviewedIrritable Bowel Syndrome

– Appendix D Supplemental Epidemiology Bibliography

– Tables and Figures

For more information visit http://www.researchandmarkets.com/research/6tdpwp/irritable_bowel

Source: Decision Resources, Inc

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing